published meta-analysis   sensitivity analysis   studies

dexamethasone in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsRashad, 2021 (REV) 0.35 [0.17; 0.74] Rashad, 2021 0.35 [0.17; 0.74] 0.35[0.21; 0.59]Rashad, 2021 (REV), Rashad, 202120%298seriousnot evaluable deathsdetailed resultsRashad, 2021 (REV) 0.46 [0.24; 0.87] Rashad, 2021 0.46 [0.24; 0.88] 0.46[0.29; 0.73]Rashad, 2021 (REV), Rashad, 202120%298seriousnot evaluable deaths (time to event analysis only)detailed resultsRashad, 2021 (REV) 0.46 [0.24; 0.87] Rashad, 2021 0.46 [0.24; 0.88] 0.46[0.29; 0.73]Rashad, 2021 (REV), Rashad, 202120%298seriousnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-05-11 09:55 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 666,1149,1150 - roots T: 290